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SUMMARY 
Glucagon-like peptide-1 (GLP-1) is an incretin hormone whose glucose-dependent 
insulinotropic actions have been harnessed as a novel therapy for glycaemic control in type 2 
diabetes. Although it has been known for some time that the GLP-1 receptor is expressed in 
the cardiovascular system where it mediates important physiological actions, it is only 
recently that specific cardiovascular effects of GLP-1 in the setting of diabetes have been 
described. GLP-1 confers indirect benefits in cardiovascular disease (CVD) under both 
normal and hyperglycaemic conditions via reducing established risk factors, such as 
hypertension, dyslipidaemia and obesity, which are markedly increased in diabetes. Emerging 
evidence indicates that GLP-1 also exerts direct effects on specific aspects of diabetic CVD, 
such as endothelial dysfunction, inflammation, angiogenesis and adverse cardiac remodelling. 
However, the majority of studies have employed experimental models of diabetic CVD and 
information on the effects of GLP-1 in the clinical setting are limited although several large-
scale trials are ongoing. It is clearly important to gain a detailed knowledge of the 
cardiovascular actions of GLP-1 in diabetes given the large number of patients currently 
receiving GLP-1 based therapies. This review will therefore discuss current understanding of 
the effects of GLP-1 on both cardiovascular risk factors in diabetes and direct actions on the 
heart and vasculature in this setting, and the evidence implicating specific targeting of GLP-1 
as a novel therapy for CVD in diabetes. 
 
 
A
cc
ep
te
d 
A
rti
cl
e
3 
This article is protected by copyright. All rights reserved. 
 
Abbreviations:  ANP (atrial natriuretic peptide); CAD (coronary artery disease); cAMP 
(cyclic adenosine monophosphate); CVD (cardiovascular disease); DPP-4 (dipeptidyl 
peptidase-4); eNOS (endothelial nitric oxide synthase); ERK (extracellular signal-regulated 
kinase); GLP-1 (glucagon-like peptide-1); GLP-1R (glucagon-like peptide-1 receptor); hs-
CRP (high sensitivity C-reactive protein); HUVEC (human umbilical vein endothelial cell); 
ICAM-1 (intercellular adhesion molecule-1); MAPK (mitogen-activated protein kinase); MI 
(myocardial infarction); MMP (matrix metalloproteinase); NF-κβ (nuclear factor kappa-light-
chain-enhancer of activated B); NO (nitric oxide); PAI-1 (plasminogen activator inhibitor-1); 
PI3K (phosphoinositide 3-kinase); PKA (protein kinase A); STZ (streptozotocin); T1DM 
(type 1 diabetes mellitus); T2DM (type 2 diabetes mellitus); TLR (toll-like receptor); TNF-α 
(tumour necrosis factor-α); UKPDS (United Kingdom Prospective Diabetes Study); VCAM-1 
(vascular cell adhesion molecule-1). 
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INTRODUCTION 
The prevalence of type 2 diabetes mellitus (T2DM) is increasing alarmingly with the 
2013 figure of 382M estimated to rise to 592M by 2035 (International Diabetes Federation, 
2014). A change in lifestyle coupled with an increase in obesity has led to a global epidemic, 
with diabetics typically carrying a 5-fold greater mortality risk as a result of cardiovascular 
disease (CVD) compared with non-diabetics (Stamler et al., 1993), with coronary artery 
disease (CAD) being the leading underlying cause (Bertoni et al., 2004). It is well established 
that hyperglycaemia plays a central role in development and progression of CVD associated 
with diabetes (Nathan, 1996). Indeed, two long-term clinical trials, the Diabetes Control and 
Complications Trial / Epidemiology of Diabetes Interventions and Complications study and 
the United Kingdom Prospective Diabetes Study (UKPDS), have demonstrated that intensive 
glucose-lowering strategies are effective in markedly reducing the incidence of microvascular 
(e.g. retinopathy, nephropathy) and macrovascular (e.g. CAD, stroke) complications in both 
type 1 diabetes mellitus (T1DM) and T2DM (Holman et al., 2008), although several similar 
large-scale trials have reported limited benefits (Action to Control Cardiovascular Risk in 
Diabetes Study Group, 2008; Duckworth et al., 2009; Ginsberg, 2011). Nonetheless, there 
remains a significant incidence of CVD even in optimally-treated diabetic patients so it is 
clear that more effective strategies are required. In this regard, the incretin peptide hormone, 
glucagon-like peptide-1 (GLP-1), has received considerable recent attention. 
The incretin effect is responsible for augmenting insulin secretion following nutrient 
ingestion, and GLP-1 together with its sister hormone, gastrointestinal peptide, account for up 
to 60% of post-prandial insulin secretion, leading to rapid blood glucose reduction (Nauck et 
al., 1986; Drucker et al., 1987). Furthermore, they possess an inherent ability to reduce 
glucagon secretion (Kreymann et al., 1987), delay gastric emptying (Näslund et al., 1998a) 
and promote satiety (Flint et al., 1998). The metabolic actions of GLP-1 are mediated by A
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GLP-1 receptor (GLP-1R) activation and stimulation of cyclic adenosine monophosphate 
(cAMP) and several downstream kinases, including extracellular signal-regulated kinase 
(ERK) 1/2, phosphoinositide 3-kinase (PI3K), and protein kinase A (PKA). Under 
physiological conditions GLP-1 has a short half-life (~2 minutes) as it is rapidly degraded by 
its endogenous inhibitor, dipeptidyl peptidase-4 (DPP-4) (Deacon et al., 1995), resulting in 
cleavage of two amino acids from native GLP-1(7-36) to produce GLP-1(9-36), which acts as 
a weak GLP-1R antagonist lacking insulinotropic activity (Green et al., 2004). However, 
emerging evidence suggests that “metabolically-inactive” GLP-1(9-36) may itself be an 
important signalling molecule (Ban et al., 2010; Gardiner et al., 2010). More detailed 
information on GLP-1 biology and signalling is provided by recent review articles (Grieve et 
al., 2009; Donnelly, 2012; Pabreja et al., 2013). 
The unique ability of GLP-1 to promote insulin secretion in a glucose-dependent 
manner has been harnessed for treatment of T2DM, with GLP-1R agonists resistant to DPP-4 
(exenatide, Byetta
®
; liraglutide (Victoza
®
), and DPP-4 inhibitors (e.g. sitagliptin, vildagliptin) 
now widely used for effective glycaemic control. Interestingly, it is well recognised that GLP-
1 exerts wide-ranging extra-pancreatic actions occurring independently of its established 
metabolic effects. Indeed, GLP-1 signalling is reported to play several important roles in the 
cardiovascular system in both health and disease (Grieve et al., 2009), although it appears that 
the GLP-1R may not be as widely expressed as previously thought. For example, recent work 
suggests that cardiac GLP-1R expression may be localised to atrial tissue, sino-atrial node and 
vasculature, with some species variation (Kim et al., 2013; Pyke et al., 2014; Richards et al., 
2014), and that earlier reports of more ubiquitous expression may be questionable due to poor 
antibody selectivity and sensitivity (Panjwani et al., 2012). Nonetheless, it is clear that GLP-1 
exerts important cardiovascular actions, although it is only recently that its effects in the 
setting of diabetes, a condition synonymous with micro/macrovascular complications, have A
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been explored. This is clearly important due to the large number of patients receiving GLP-1 
based therapies, in which its cardiovascular actions are largely unknown. This review will 
therefore discuss current understanding of the effects of GLP-1 on both cardiovascular risk 
factors in diabetes and direct actions on the heart/vasculature in this setting, and the evidence 
implicating specific targeting of GLP-1 as a novel therapy for CVD in diabetes, with a 
primary focus on the role of GLP-1R agonists. More detailed discussion of the pleiotropic 
actions of DPP-4 inhibitors in this setting, is provided by recent review articles specifically 
focused on this important aspect of cardiovascular GLP-1 signalling (Scheen, 2013; Aroor et 
al., 2014). 
 
INFLUENCE OF GLP-1 ON CARDIOVASCULAR RISK FACTORS IN DIABETES 
Blood pressure and hypertension 
Increased blood pressure is an established risk factor for CVD in both 
normoglycaemia and T2DM (Turner et al., 1998; Vasan et al., 2001). Notably, therapeutic 
reduction of blood pressure and circulating glucose has an additive effect in decreasing 
cardiovascular complications in T2DM patients, as highlighted by the UKPDS (Stratton et al., 
2006). Indeed, in an experimental setting, chronic GLP-1 infusion inhibits development of 
hypertension in Dahl salt-sensitive rats, as well as reducing cardiac fibrosis and hypertrophy, 
effects which appear to occur via a natriuretic/diuretic mechanism independently of blood 
glucose (Yu et al., 2003), suggesting that GLP-1 may confer additional benefits which could 
be harnessed for the treatment of hypertension associated with T2DM. Consistent with an 
indirect blood pressure-lowering effect, it was recently reported that liraglutide-stimulated 
reduction of angiotensin II-induced hypertension in mice was blocked by the natriuretic 
peptide receptor antagonist, ananin, in a GLP-1R dependent manner, but unaltered by the 
nitric oxide (NO) synthase inhibitor, L-NMMA, and that liraglutide induced rapid increases in A
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atrial natriuretic peptide (ANP) secretion both in vivo and in isolated perfused hearts, 
suggesting that observed blood pressure reduction occurred at least partly via direct activation 
of cardiac ANP (Kim et al., 2013). Importantly, in the context of diabetes, the GLP-1 
mimetic, exendin-4, inhibited development of both spontaneous and high salt-induced 
hypertension in obese db/db mice via beneficial actions on renal sodium handling (Hirata et 
al., 2009). Furthermore, it was recently reported that treatment of insulin-resistant Zucker rats 
with the DPP-4 inhibitor, linagliptin, for 8 weeks reduced blood pressure and improved 
diastolic function (Aroor et al., 2013). 
Interestingly, although chronic administration of GLP-1 may prevent development of 
hypertension, it is widely reported that acute GLP-1 exposure is associated with increased 
blood pressure and heart rate, which predisposes to CVD. For example, acute infusion of 
GLP-1(7-36) increased systolic/diastolic blood pressure and heart rate in both normal and 
insulin-deficient streptozotocin (STZ)-induced T1DM rats (Barragan et al., 1994), with the 
same group reporting that exendin-4 induced increases in blood pressure and heart rate were 
reversed by the GLP-1R antagonist, exendin(9-39) (Barragan et al., 1996), suggesting that 
these effects occurred via an insulin-independent mechanism but involving GLP-1R 
activation. Although similar increases in blood pressure and heart rate after short-term GLP-1 
administration have been reported in various experimental models (Grieve et al., 2009), the 
data from clinical studies are less clear. For example, GLP-1 infusion in a small number of 
T2DM patients with or without CAD for 105 minutes and 48 hours, respectively, had no 
effect on heart rate or systolic/diastolic blood pressure (Toft-Nielsen et al., 1999; Nystrӧm et 
al., 2004), whereas 48-hour GLP-1 infusion in patients with ischaemic heart failure (Halbirk 
et al., 2010), and treatment of T2DM patients with an exendin-transferrin fusion protein or 
exenatide for 7 or 10 days, respectively (Kothare et al., 2008; Gustavson et al., 2011), resulted 
in elevated heart rate and diastolic blood pressure. However, the data from longer-term GLP-1 A
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clinical trials are more consistent, with the majority reporting decreased blood pressure and 
minimal effects on heart rate. For example, the LEAD-4 (Liraglutide Effect and Action in 
Diabetes) study, investigating 26-week liraglutide treatment in combination with metformin 
in T2DM patients, reported a modest reduction in systolic blood pressure of 6mmHg 
compared to placebo (1.1mmHg) (Zinman et al., 2009). Similarly, the LEAD-2 study, 
assessing liraglutide combination therapy, reported a 2-3mmHg decrease in systolic blood 
pressure versus a small increase (0.4mmHg) in the glimepiride control group (Nauck et al., 
2009). Furthermore, a 30-week trial comparing once-weekly versus twice-daily exenatide 
injection in drug-naïve T2DM patients observed a significant decrease in systolic/diastolic 
blood pressure compared to baseline (Drucker et al., 2008), whilst another 20-week trial in 
obese patients reported reduced systolic/diastolic blood pressure in response to liraglutide, 
which persisted for the 2 year follow-up period (Astrup et al., 2012). Interestingly, meta-
analysis of 6 clinical trials comprising 2171 T2DM patients found that exenatide treatment for 
6 months produced maximal systolic blood pressure reduction in individuals with abnormally 
high baseline levels, whereas no effects were observed in normotensive subjects (Okerson et 
al., 2010). It should be noted that blood pressure reduction is positively correlated with weight 
loss (Neter et al., 2003), so it is possible that the observed changes after chronic GLP-1 
treatment may occur secondary to its metabolic effects. However, although beneficial effects 
of GLP-1 on body weight are associated with improved hypertension, it is clear that this 
cannot solely account for its vascular effects as several studies have reported blood pressure 
reduction prior to weight loss. For example, a combined meta-analysis of three 26-week 
liraglutide trials reported decreased blood pressure after only 2 weeks, whilst maximal weight 
loss did not occur until 8 weeks (Gallwitz et al., 2010). Indeed, heart rate, which is not linked 
to body weight, was increased by chronic administration of both liraglutide and exenatide in 
T2DM patients in parallel with reduced systolic blood pressure (Garber et al., 2009; Gill et A
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al., 2010). Interestingly, it was recently reported that GLP-1 secretory function increases with 
age and is negatively correlated with systolic blood pressure, suggesting that this may 
represent an adaptive response (Yoshihara et al., 2013). 
 
Dyslipidaemia 
The pathophysiology of diabetes is commonly considered largely in terms of 
associated hyperglycaemia. However, it is increasingly apparent that dyslipidaemia is equally 
important and represents a significant risk factor for CVD in diabetic patients (Reiner et al., 
2011). It is likely that impaired insulin sensitivity contributes to dyslipidaemia in T2DM, 
which is associated with reduced GLP-1 secretion. Indeed, in addition to their established 
glycaemic actions, GLP-1R activation and DPP-4 inhibition are reported to improve lipid 
profiles in both experimental and clinical diabetes. For example, short-term infusion of GLP-1 
in normoglycaemic Syrian golden hamsters decreased lipid absorption and triglyceride levels, 
an effect potentiated by oral glucose (Hein et al., 2013), suggesting that its incretin action may 
inhibit intestinal production of chylomicrons, which are strongly linked to atherosclerosis 
(Nakano et al., 2008). Similarly, circulating triglycerides and fat pad mass in rats with diet-
induced obesity were reduced after 4-week treatment with liraglutide (Madsen et al., 2010), 
whilst 40-day administration of exendin-4 ameliorated systemic and cardiac insulin resistance 
and dyslipidaemia in both genetic KKAy and diet-induced T2DM mouse models (Monji et 
al., 2013). Furthermore, chronic GLP-1R activation with both the GLP-1 analogue, 
CNTO3649, and exendin-4 in apolipoprotein E3-Leiden transgenic mice, which develop 
severe hypercholesterolaemia after high-fat feeding, resulted in reduced VLDL-triglyceride 
and apolipoprotein B synthesis in parallel with decreased hepatic triglyceride, cholesterol and 
phospholipids and lipogenesis gene expression (Parlevliet et al., 2012). The long-acting DPP-A
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4 inhibitor, teneligliptin, is also reported to decrease circulating triglyceride and free fatty acid 
levels in insulin-resistant Zucker fatty rats after 2-week treatment (Fukuda-Tsuru et al., 2012). 
Importantly, the majority of clinical studies have also demonstrated beneficial 
outcomes of GLP-1 administration on lipid metabolism in T2DM, such as reduced circulating 
triglycerides and LDL cholesterol (Flock et al., 2007; Drucker et al., 2008; Tremblay et al., 
2011), although one study in which patients were treated with exenatide for 24 weeks 
reported a similar plasma lipid profile versus controls (Moretto et al., 2008). For example, 
decreased circulating levels of atherogenic triglyceride-rich lipoproteins were observed 
following 4-week vildagliptin monotherapy in drug naïve T2DM patients, characterised by 
specific reductions in total plasma and chylomicron triglycerides, together with 
apolipoprotein B-48 and cholesterol in the chylomicron sub-fraction (Matikainen et al., 2006). 
Furthermore, the LEAD-4 study found that 26-week liraglutide treatment in combination with 
metformin and rosiglitazone decreased circulating LDL cholesterol, triglycerides and free 
fatty acids in T2DM patients compared to placebo controls, although it is interesting to note 
that these changes were greater in response to low-dose treatment (Zinman et al., 2009). 
Indeed, similar results are reported for DPP-4 inhibitors, which produce much lower 
circulating levels of GLP-1. For example, twice-daily sitagliptin led to significant reduction of 
circulating triglycerides and free fatty acids in a large number of T2DM patients compared to 
placebo and glipizide control groups, despite similar decreases in fasting plasma glucose and 
HbA1C levels (Scott et al., 2007). Interestingly, a single injection of exenatide was shown to 
attenuate postprandial increases in triglycerides, apolipoprotein B-48 and CIII/remnant 
lipoprotein cholesterol for up to 8 hours in patients with impaired glucose tolerance and 
recent-onset T2DM (Schwartz et al., 2010), suggesting that such lipid profile benefits may not 
be explained solely by chronic changes in body weight, glucose levels and insulin resistance. 
Indeed, it was recently reported that exendin-4 completely reverses hepatic steatosis in mice A
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fed a high-fat diet via a GLP-1R dependent mechanism resulting in reduced numbers/size of 
circulating VLDL-triglyceride and VLDL-apolipoprotein B particles (Parlevliet et al., 2012), 
suggesting that GLP-1 may exert direct effects on dyslipidaemia in diabetes. 
 
Obesity 
Although it is well known that obesity significantly increases risk of T2DM (Willett et 
al., 1999), and both are independent risk factors for CVD (Hubert et al., 1983), many 
established diabetes therapies, including sulfonylureas and thiazolidinediones, may increase 
body weight. However, GLP-1 reduces body weight due to beneficial effects on glucagon 
secretion, gastric emptying and satiety (Kreymann et al., 1987; Flint et al., 1998; Näslund et 
al., 1998a), so it seems likely that impaired GLP-1 secretion observed in non-diabetic obese 
individuals (Holst et al., 1982; Näslund et al., 1998b), may at least partly account for their 
increased body weight. Indeed, weight loss improves the postprandial GLP-1 response in 
severely-obese patients (Verdich et al., 2001), suggesting that the two are interlinked. 
Furthermore, 20-week treatment with liraglutide was reported to cause significant weight loss 
in obese individuals and to reduce incidence of pre-diabetes (Astrup et al., 2009), confirming 
an apparent role for GLP-1 in weight control which may be harnessed for therapeutic benefit. 
This assertion is supported by the LEAD trials which have consistently reported body weight 
reduction in T2DM patients following liraglutide treatment (Moretto et al., 2008; Buse et al., 
2009; Garber et al., 2009; Nauck et al., 2009, 2013; Zinman et al., 2009). For example, in the 
LEAD-2 trial, 26-week combination therapy of liraglutide with metformin in T2DM patients 
resulted in increased weight loss compared to metformin alone (Nauck et al., 2013). 
Importantly, weight loss associated with both liraglutide and exenatide treatment is reported 
to be linked with improved cardiovascular risk factors, such as HbA1c and blood pressure, 
and to persist for at least two years (Klonoff et al., 2007; Astrup et al., 2009, 2012), A
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highlighting important benefits of GLP-1 which may not be related to its insulinotropic 
actions. The long-term effects of GLP-1 on weight loss may be particularly important as 
conventional weight loss is typically poorly maintained in T2DM patients. Despite GLP-1R 
agonists promoting weight loss in both diabetic and non-diabetic obese subjects, DPP-4 
inhibitors appear to be weight-neutral (Amori et al., 2007), suggesting that GLP-1R agonists 
may exert direct gastrointestinal effects in addition to improving insulin resistance (Rask et 
al., 2001), although this could simply be due to differences in circulating GLP-1 levels. 
However, postprandial GLP-1 levels are reported to be increased immediately after gastric 
bypass surgery, despite patients remaining obese, indicating that GLP-1 may regulate appetite 
and food intake directly (Morinigo et al., 2006). Indeed, in T2DM patients GLP-1 promotes 
satiety, thereby reducing energy consumption (Gutzwiller et al., 1999), whilst in healthy 
individuals intravenous administration of GLP-1(7-36) slows gastric emptying in a dose-
dependent manner (Nauck et al., 1997). 
 
GLP-1 AND VASCULAR DISEASE 
Vascular function 
Impaired endothelial and vascular function are established as key initiating factors 
underlying development of microvascular and macrovascular complications associated with 
diabetes. Indeed, it has been known for some time that native GLP-1(7-36) induces ex vivo 
dose-dependent vasodilatation in a number of isolated rodent vessels, including aorta (Golpon 
et al., 2001; Green et al., 2008), pulmonary artery (Richter et al., 1993; Golpon et al., 2001), 
femoral artery (Nystrӧm et al., 2005), and mesenteric artery (Ban et al., 2008), although 
several different mechanisms have been proposed. For example, some studies indicate that the 
vasorelaxant actions of GLP-1 are dependent upon endothelium-derived NO (Golpon et al., 
2001; Ban et al., 2008; Gaspari et al., 2011), whereas others have proposed endothelium-A
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independent mechanisms involving mediators such as KATP channels, cAMP and β2-
adrenoceptor activation (Nystrӧm et al., 2005; Gardiner et al., 2008; Green et al., 2008). 
Interestingly, although several studies suggest that the vascular actions of GLP-1 are 
dependent upon the GLP-1R (Gaspari et al., 2011; Chai et al., 2012), it appears that they may 
also be mediated, at least partly, by its truncated metabolite, GLP-1(9-36), which induces 
dose-dependent relaxation in both isolated mouse mesenteric artery  (Ban et al., 2008) and rat 
aorta (Green et al., 2008). It should be noted that although the synthetic GLP-1 mimetic, 
exendin-4, exerts similar actions in rat aorta (Golpon et al., 2001; Green et al., 2008), they are 
of reduced magnitude compared to GLP-1(7-36) and are absent in mouse mesenteric artery 
(Ban et al., 2008). Importantly, the vasorelaxant actions of GLP-1 are also reported in vivo. 
For example, systemic administration of GLP-1(7-36) by both bolus dose and short-term 
infusion in rats induced hindquarters vasodilation (Gardiner et al., 2010). Interestingly, 
however, GLP-1 promoted vasoconstriction in both mesenteric and renal arteries, whilst 
exendin-4 exerted similar vasoconstriction in mesenteric artery but induced vasodilatation in 
both hindquarters and renal artery (Gardiner et al., 2008), suggesting differential vascular 
effects. Indeed, a similar study demonstrated that GLP-1(7-36) infusion acutely increased 
muscle microvascular blood volume in the absence of changes in microvascular blood flow 
velocity or femoral blood flow, in association with increased plasma NO, muscle insulin 
clearance/uptake, hindlimb glucose extraction and muscle interstitial oxygen saturation (Chai 
et al., 2012). It should be noted that in contrast to the ex vivo studies, GLP-1(9-36) failed to 
modulate vascular function in rats in vivo when given as either a bolus dose or via short-term 
infusion, which together with the fact that DPP-4 inhibitors prolonged the vascular actions of 
native GLP-1(7-36) in this setting (Gardiner et al., 2010), suggest that the actions of this 
“inactive” metabolite may not be significant in vivo. A
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Importantly, it appears that the vascular effects of GLP-1 are also evident in the 
setting of diabetes, where they are reported to promote beneficial actions. Chronic treatment 
of STZ/nicotinamide T1DM rats with either GLP-1(7-36) or exendin-4 was shown to prevent 
endothelial dysfunction in parallel with reduction of blood glucose (Özyazgan et al., 2005), 
effects which may be mediated via activation of endothelial NO synthase (eNOS) (Goyal et 
al., 2010). Although similar studies have not been performed in the setting of overt T2DM, it 
was recently reported that chronic treatment of insulin-resistant Zucker rats with the DPP-4 
inhibitor, linagliptin, resulted in reduced hypertension in parallel with increased expression of 
total/phosphorylated eNOS (Aroor et al., 2013). Furthermore, high-fat fed apolipoprotein E-
deficient mice treated with a different DPP-4 inhibitor, des-fluoro-sitagliptin, demonstrated 
attenuation of endothelial dysfunction in parallel with eNOS activation and improved glucose 
tolerance (Matsubara et al., 2012). Interestingly, however, endothelial dysfunction in rat 
femoral artery induced by short-term triglyceride exposure was not affected by exendin-4 
(Nathanson et al., 2009), suggesting that the reported in vivo protective actions may occur via 
indirect mechanisms. In this regard, it is important to note that the vascular actions of GLP-1 
in diabetes are likely to occur, at least partly, secondary to stimulation of insulin, which 
induces vascular relaxation via Ca
2+
-dependent activation of eNOS (Han et al., 1995; Kahn et 
al., 1998). 
In addition to data supporting important vascular actions of GLP-1 in experimental 
diabetes, several studies have reported beneficial functional effects in the clinical setting. For 
example, in T2DM patients with stable CAD, acute GLP-1 administration improved brachial 
artery flow-mediated vasodilation, an effect not observed in healthy individuals (Nystrӧm et 
al., 2004). Comparable effects were observed in insulin-resistant patients with obesity-related 
metabolic syndrome, where acute treatment with GLP-1(7-36) enhanced insulin-mediated 
forearm blood flow responses to both acetylcholine and sodium nitroprusside in the absence A
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of changes in forearm glucose extraction/uptake, whilst GLP-1(9-36) did not affect vascular 
function (Tesauro et al., 2013). Similarly, in patients with T1DM, brachial artery endothelial 
dysfunction induced by acute blood glucose modulation was counteracted by simultaneous 
infusion of GLP-1 (Ceriello et al., 2013). Interestingly, GLP-1-induced enhancement of 
endothelium-dependent peripheral vasodilatation observed in non-diabetic individuals is 
differentially modulated by sulphonylureas, with glyburide abolishing GLP-1 induced 
acetycholine-mediated responses which are unaltered by glimepiride (Basu et al., 2007). 
Furthermore exenatide, which is commonly used for hyperglycaemic control in T2DM, also 
increased postprandial endothelial function assessed by peripheral arterial tonometry in 
patients with recent-onset disease when given as a single dose, largely secondary to reduction 
of circulating triglycerides (Koska et al., 2010), although chronic treatment for 3 months in 
obese pre-diabetic patients had no additional effect when compared to those receiving 
metformin (Kelly et al., 2012). Whilst it appears that clinical GLP-1 administration exerts 
acute vascular effects in T2DM, data on its chronic actions in this setting are variable. T2DM 
patients who received exenatide for a period of 4 months as an adjunct to standard metformin 
therapy demonstrated improved brachial artery flow-mediated dilatation, indicated by 
elevated peak dilatation and shear rate which are reflective of improved macrovascular and 
microvascular function, respectively (Irace et al., 2013). Notably, enhanced vasodilatation in 
exenatide-treated patients in this study was significantly greater than that observed in those 
receiving glimepiride as an add-on to metformin therapy. Furthermore, liraglutide treatment 
for 12 weeks in T2DM patients well controlled on metformin monotherapy resulted in 
improvement of both circulating markers of vascular function (asymmetric dimethylarginine, 
ADMA; plasminogen activator inhibitor-1, PAI; E-selectin) and retinal microvascular 
endothelial function (Forst et al., 2012). However, a similar study in a small number of 
severely-obese T2DM patients chronically-treated with GLP-1R agonists for 6 months A
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reported that neither exenatide or liraglutide had any effect on brachial artery endothelial-
dependent flow-mediated dilation (Hopkins et al., 2013), indicating potential for other 
confounding factors in this setting which may need to be considered. Furthermore, 6-week 
treatment with sitagliptin or alogliptin significantly reduced flow-mediated dilatation in male 
T2DM patients (Ayaori et al., 2013), suggesting that chronically-increased physiological 
levels of GLP-1 may exert unfavourable vascular actions, although it is possible that this 
could be a class-specific effect of DPP-4 inhibitors warranting further investigation. 
 
Inflammation and atherosclerosis 
It is well known that the incidence and progression of endothelial dysfunction is 
exacerbated in T2DM, secondary to established risk factors, such as insulin resistance, 
dyslipidaemia and hyperglycaemia. Endothelial dysfunction in this setting is characterised by 
elevation of circulating adhesion molecules, such as intercellular adhesion molecule-1 
(ICAM-1) vascular cell adhesion molecule-1 (VCAM-1), and an increased propensity to 
develop atherosclerosis which is typified by inflammatory cell infiltration and plaque 
formation (van Gaal et al., 2006). Interestingly, several recent clinical and experimental 
studies appear to indicate that GLP-1 exerts both anti-inflammatory and anti-atherogenic 
actions. For example, GLP-1 treatment in T2DM patients is associated with beneficial effects 
on a number of established CVD biomarkers, including high sensitivity C-reactive protein 
(hs-CRP) and plasminogen activator inhibitor-1 (PAI-1), which are important in 
atherosclerosis development (Haffner, 2006). Similarly, 14-week treatment of T2DM patients 
with liraglutide resulted in significantly reduced PAI-1 levels, and a dose-dependent decrease 
in plasma hs-CRP levels (Vilsbøll et al., 2007; Courrèges et al., 2008), an effect that was also 
observed after 26-week treatment with exenatide (Bergenstal et al., 2010), and was over and 
above that seen in patients treated with insulin glargine (Diamant et al., 2010). Importantly, A
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the beneficial effects of exenatide on circulating hs-CRP appear to persist at 1 year treatment 
in T2DM patients receiving standard metformin therapy, resulting in reduced levels of both 
hs-CRP and leptin (Bunck et al., 2010). DPP-4 inhibitors seem to exert similar effects as 
T2DM patients receiving sitagliptin for 6 months also demonstrated significant reductions in 
plasma hs-CRP, together with VCAM-1 and associated albuminuria, which may attenuate 
glucose excursion and inhibit vascular inflammation (Horváth et al., 2009; Hattori, 2010). 
Interestingly, a recent study demonstrated that cessation of exenatide treatment resulted in 
reversal of benefits on circulating hs-CRP within 6 months (Varanasi et al., 2011). It should 
be noted that although these studies support the suggestion that GLP-1 may protect against 
inflammation and atherosclerosis in the clinical setting, it is not possible to draw clear 
conclusions due to the absence of longer-term studies specifically assessing effects on disease 
development. Interestingly, a recent study has reported a positive correlation between 
circulating GLP-1 levels and CAD in both diabetic and non-diabetic patients undergoing 
angiography due to typical or atypical chest pain, highlighting the possibility that GLP-1 may 
exert detrimental effects in this setting (Piotrowski et al., 2013). 
Nonetheless, the majority of clinical data are broadly supportive of anti-inflammatory 
actions of GLP-1, which persist for up to 12 weeks in obese T2DM patients after a single 
exenatide injection (Chaudhuri et al., 2011). Indeed, in this study GLP-1 was associated with 
specific reduction of several inflammatory mediators, including tumour necrosis factor-α 
(TNF-α), toll-like receptor-2 (TLR-2) and TLR-4, in parallel with suppression of nuclear 
factor kappa-light-chain-enhancer of activated B (NF-κβ) signalling and matrix 
metalloproteinase-9 (MMP-9) activity, which are key initiating factors of atherosclerosis. 
Furthermore, in obese T2DM patients, 8-week liraglutide treatment is reported to decrease 
levels of the inflammatory macrophage activation molecule, sCD163, and pro-inflammatory 
cytokines, TNF-α and interleukin-6, whilst increasing levels of the anti-inflammatory A
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adipokine, adiponectin (Hogan et al., 2014). Importantly, these clinical observations are 
supported by a number of experimental studies which have specifically assessed the effects of 
GLP-1 on development and progression of atherosclerosis. For example, continuous infusion 
of exendin-4 in both wild-type and apolipoprotein E-deficient normoglycaemic mice was 
reported to decrease monocyte adhesion and development of atherosclerotic lesions in 
thoracic aorta, effects proposed to occur via cAMP/PKA-dependent suppression of 
inflammation (Arakawa et al., 2010). These findings were confirmed by a different group who 
demonstrated reduced aortic macrophage recruitment, foam cell formation and atherosclerotic 
lesion development in apolipoprotein E-deficient mice after GLP-1 infusion (Nagashima et 
al., 2011). Furthermore, chemokine-induced migration of CD4
+
 lymphocytes is inhibited by 
both GLP-1(7-36) and exendin-4 in a GLP-1R dependent manner (Marx et al., 2010), whilst 
liraglutide supresses NF-κβ signalling in human umbilical vein endothelial cells (HUVECs) 
and THP-1 monocyte adhesion in human aortic endothelial cells via downstream activation of 
several pro-inflammatory and cell adhesion molecules, including TNF-α, VCAM-1 and E-
selectin (Shiraki et al., 2012; Krasner et al., 2014). Indeed, liraglutide inhibits TNFα in human 
vascular endothelial cells and reduces hyperglycaemia-mediated PAI-1, ICAM-1 and VCAM-
1 activation, which is associated with endothelial dysfunction and accelerated atherogenesis in 
T2DM (Liu et al., 2009). Furthermore, the DPP-4 inhibitor, des-fluoro-sitagliptin, is reported 
to exert cAMP-dependent anti-inflammatory actions in cultured human macrophages by 
increasing GLP-1 levels and to reduce atherosclerotic lesion formation in apolipoprotein E-
deficient mice (Matsubara et al., 2012), whilst alogliptin inhibits vascular 
monocyte/macrophage recruitment and reduces atherosclerotic burden in high-fat fed LDL 
receptor-deficient mice in association with improvement of metabolic indices (Shah et al., 
2011). Taken together, these experimental data clearly support an important role for GLP-1 in 
protecting against vascular inflammation and atherogenesis, effects which are borne out by A
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the reported clinical benefits of GLP-1 treatment on circulating inflammatory mediators and 
CVD biomarkers. However, it is evident that long-term studies specifically investigating 
effects on atherosclerotic disease development and progression are required to ascertain 
whether the apparent protective effects of GLP-1 under both normoglycaemic and diabetic 
conditions may translate to the clinical setting. 
 
Angiogenesis 
Abnormal angiogenesis is a hallmark of CVD which is exacerbated by diabetes, with 
impaired neovascularisation contributing significantly to progression of ischaemic disease 
associated with peripheral and coronary arteries. Interestingly, it is becoming apparent that 
GLP-1 may modulate angiogenesis suggesting that such actions may underlie some of its 
reported beneficial cardiovascular effects. For example, exendin-4 stimulates proliferation of 
human coronary artery endothelial cells in a GLP-1R dependent manner via downstream 
activation of eNOS, PKA and PI3K/Akt signalling (Erdogdu et al., 2010) and promotes in 
vitro HUVEC migration, ex vivo aortic sprouting angiogenesis, and in vivo blood vessel 
formation in Matrigel plugs (Kang et al., 2013), whilst native GLP-1(7-36) stimulates in vitro 
angiogenesis in HUVECs via Akt, Src and protein kinase C-dependent pathways (Aronis et 
al., 2013), suggesting that GLP-1 may directly modulate neovascularisation. Importantly, 
these effects appear to translate to the pathological situation, with several recent studies 
reporting that GLP-1 can promote the pro-angiogenic actions of mesenchymal stem cells in 
different disease settings. Intra-coronary artery delivery of GLP-1 eluting encapsulated human 
mesenchymal stem cells in a porcine model of experimental myocardial infarction (MI) 
resulted in improved left ventricular function and remodelling which was associated with 
increased infarct zone angiogenesis (Wright et al., 2012), whilst peri-adventitial treatment of 
porcine vein grafts with these cells inhibited neointima formation in parallel with accelerated A
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adventitial angiogenesis (Huang et al., 2013). Furthermore, the addition of GLP-1 to 
encapsulated human mesenchymal cells significantly improved blood flow recovery and foot 
salvage in a mouse model of hindlimb ischaemia via increased capillary and arteriole 
formation secondary to paracrine activation of vascular endothelial growth factor-A (Katare et 
al., 2013). Although the majority of work investigating the pro-angiogenic actions of GLP-1 
has been performed in normoglycaemic models, a recent study reported similar beneficial 
effects in the setting of diabetes. Impaired myocardial angiogenesis in STZ-treated T1DM rats 
and associated fibrosis and diastolic dysfunction were reversed by genetic deletion of DPP-4 
or pharmacological inhibition with vildagliptin (Shigeta et al., 2012). Interestingly, this study 
identified DPP-4 as being membrane-bound and localised to the cardiac capillary endothelium 
with increased expression in diabetes, which together with a report of increased binding 
affinity of GLP-1 to the coronary endothelium but not cardiomyocytes in isolated perfused 
T1DM rat hearts (Barakat et al., 2011), supports a key endothelial-specific role of GLP-1 in 
this setting. Although these data provide supportive evidence for pro-angiogenic actions of 
GLP-1 in diabetes, it is clear that additional mechanistic studies are required using different 
CVD models in order to define its precise role. Furthermore, it is important to assess the 
effects of GLP-1 therapy in diabetic patients in order to investigate whether the apparent pro-
angiogenic effects of GLP-1 translate to the clinical setting and are of functional relevance. 
 
GLP-1 AND THE DIABETIC MYOCARDIUM 
The heart is one of the major organ targets of GLP-1 and an increasing number of 
studies have investigated the actions of native GLP-1(7-36), GLP-1R agonists and DPP-4 
inhibitors in the context of cardioprotection. The majority of experimental studies have 
focused on the effects of GLP-1 in cardiac ischemia and its apparent ability to protect against 
acute myocardial damage. Indeed, it is well established that GLP-1 pre-treatment and chronic A
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DPP-4 inhibition reduce infarct size after experimental ischaemia in both small and large 
animal models, which is associated with increased survival and improved cardiac function 
(Bose et al., 2005; Ban et al., 2008, 2010; Timmers et al., 2009). Interestingly, a recent study 
employing a rabbit model of ischaemia/reperfusion injury, reported protective actions of 
transferrin-stabilised GLP-1, when given both 12 hours prior to ischaemia and immediately 
upon reperfusion, suggesting that GLP-1 may limit infarct size and contractile dysfunction 
directly, rather than by pre-conditioning the heart against ischaemia, as suggested by previous 
reports (Matsubara et al., 2011). In addition to its established beneficial actions against acute 
ischaemic myocardial damage, GLP-1 also confers protection against contractile dysfunction 
associated with experimental chronic post-MI remodelling, dilated cardiomyopathy and 
hypertensive heart failure (Nikolaidis et al., 2004a; Poornima et al., 2008; Liu et al., 2010), 
with similar results reported in the clinical setting in response to short-term GLP-1 treatment 
(Nikolaidis et al., 2004b; Sokos et al., 2006). 
Until recently, only limited data were available on the cardiac actions of GLP-1 in 
diabetes, but it is becoming increasingly apparent that GLP-1 also plays a key 
cardioprotective role in this setting. This is important as it is well known that hyperglycaemia 
is associated with increased susceptibility to cardiac disease and poor outcomes in both 
humans and experimental models (Shiomi et al., 2003; Liu et al., 2005; Greer et al., 2006; 
Vergès et al., 2007). Chronic DPP-4 inhibition with linagliptin improves obesity-related 
diastolic dysfunction in insulin-resistant Zucker rats, but has no effect on cardiomyocyte 
hypertrophy and fibrosis (Aroor et al., 2013). Indeed, exendin-4 has been reported to directly 
protect isolated rat cardiomyocytes from high glucose-induced apoptosis via inhibition of 
endoplasmic reticulum stress and activation of sarcoplasmic reticulum Ca
2+
 ATPase 2a 
(Younce et al., 2013). GLP-1 also appears to protect against diabetic cardiomyopathy, which 
is defined as cardiac dysfunction in the absence of, or disproportionate to, associated A
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hypertension and CAD, and is characterised by marked collagen accumulation and impaired 
diastolic function (Bugger and Abel, 2014). Both GLP-1R activation and DPP-4 inhibition 
attenuate development of cardiac dysfunction, extracellular matrix remodelling, 
cardiomyocyte hypertrophy and apoptosis in experimental models of T1DM and T2DM, with 
various mechanisms proposed including reduction of lipid accumulation, oxidative stress and 
myocardial inflammation, and modulation of the MMP-2/tissue inhibitor of MMP-2 axis, 
endoplasmic reticulum stress and microvascular barrier function (Shigeta et al., 2012; Liu et 
al., 2013; Monji et al., 2013; Picatoste et al., 2013; Wang et al., 2013). Furthermore, it appears 
that GLP-1 also confers infarct-reducing actions in diabetes, which is associated with 
increased susceptibility to myocardial ischaemia. For example, mice made diabetic by a 
combination of STZ injection and high-fat feeding and treated with the GLP-1R agonist, 
liraglutide, prior to coronary artery ligation, demonstrated reduced infarct development and 
improved survival compared to those treated with the glucose-lowering drug, metformin, 
suggesting that the observed effects occurred via direct actions on the heart and not secondary 
to reduced blood glucose (Noyan-Ashraf et al., 2009). Similar cardioprotective effects have 
been reported with DPP-4 inhibition in experimental diet-induced obesity (Huisamen et al., 
2013), whilst the infarct-limiting effects of exendin-4 in mice with T2DM were shown to be 
mediated by cAMP-induced PKA activation (Ye et al., 2013). Interestingly, it has recently 
been suggested that the infarct-reducing actions of DPP-4 inhibitors may be glucose-
dependent, as both sitagliptin and vildagliptin were found to only decrease infarct size in 
isolated rat hearts subjected to ischaemia-reperfusion injury when they were perfused with 
elevated glucose concentrations ≥7mmol/L, with similar results observed in vivo in diabetic, 
but not normoglycaemic rats (Hausenloy et al., 2013). This raises the intriguing possibility 
that glucose-lowering may counteract the cardioprotective actions of GLP-1 and explain why 
several large-scale clinical trials focused on intensive glucose control in T2DM have failed to A
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demonstrate significant cardiovascular benefits (Giorgino et al., 2013). Furthermore, it 
appears that at least part of the observed beneficial actions of DPP-4 inhibitors against 
ischaemia-reperfusion injury may be mediated by the chemokine, stromal cell-derived factor 
1α, in a GLP-1 independent manner (Bromage et al., 2014). 
In addition to the experimental data highlighting a protective role for GLP-1 in the 
diabetic heart, importantly, a small number of studies have assessed its cardiac actions in 
patients with diabetes. It has been known for some time that short-term GLP-1 treatment 
exerts beneficial effects in clinical heart failure in both normoglycaemic and diabetic patients. 
For example, in a small number of heart failure patients (New York Heart Association class 
III/IV), 5-week infusion with GLP-1 plus standard therapy improved left ventricular ejection 
fraction and myocardial oxygen consumption compared to those receiving standard therapy 
alone, effects that were seen in both diabetic and non-diabetic patients (Sokos et al., 2006). 
Furthermore, a small non-randomised trial of 72-hour GLP-1 infusion following primary 
angioplasty after acute MI led to improved cardiac function in both non-diabetic and diabetic 
patients which was still evident upon 120 day follow-up (Nikolaidis et al., 2004b). More 
recently, a larger randomised trial in patients presenting with ST-segment elevation MI 
reported that exenatide infusion for 15 minutes prior to primary angioplasty continued until 6 
hours post reperfusion resulted in improved myocardial salvage at 3 months although no 
functional benefits were observed (Lønborg et al., 2012). Indeed, two current clinical trials are 
assessing the potential of using exenatide as a post-conditioning agent to reduce reperfusion 
injury following percutaneous coronary intervention (Effect of Additional Treatment With 
EXenatide in Patients With an Acute Myocardial Infarction, the EXAMI trial, NCT01254123; 
Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI, POSTCON 
II, NCT00835848). Interestingly, in patients with left ventricular diastolic dysfunction, DPP-4 
activity in the coronary sinus and peripheral circulation is reported to be negatively correlated A
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with diastolic function and increased by comorbid diabetes (Shigeta et al., 2012), suggesting 
that reduced GLP-1 levels in diabetes may underlie associated cardiac dysfunction. Exenatide 
has also been found to modulate myocardial glucose transport and uptake in T2DM patients 
dependent upon the degree of insulin resistance (Gejl et al., 2012), although a similar study 
reported that GLP-1 induced increases in resting myocardial glucose uptake in lean 
individuals were absent in obese T2DM patients, with parallel studies in pigs suggesting that 
this was due to impaired p38-mitogen-activated protein kinase (MAPK) signalling (Moberly 
et al., 2013). Interestingly, a recent experimental study found that exendin-4 reduced 
contractile function and was unable to stimulate glucose utilisation in normal rat hearts in the 
presence of fatty acids (Nguyen et al., 2013), despite previous reports of increased myocardial 
glucose uptake in response to GLP-1 in experimental myocardial ischaemia and dilated 
cardiomyopathy (Nikolaidis et al., 2005; Zhao et al., 2006; Bhashyam et al., 2010). Such 
findings highlight the need for detailed investigation of the effects of GLP-1 on altered 
myocardial metabolism in diabetic patients both with and without cardiac complications, in 
which the effects of GLP-1 may diverge. 
Although these clinical and experimental data are clearly supportive of an important 
role for GLP-1 signalling in the diabetic heart, they are largely descriptive with limited focus 
on underlying mechanisms. Previous studies in experimental models of heart failure have 
highlighted several pathways which may mediate the cardioprotective effects of GLP-1, 
including cAMP/PKA, PI3K/Akt, p44/p42MAPK, ERK1/2 (Bose et al., 2005; Timmers et al., 
2009; Ravassa et al., 2011), together with suggestions of GLP-1R independent signalling 
(Nikolaidis et al., 2005; Sonne et al., 2008). However, the precise mechanisms underlying the 
apparent protective actions of GLP-1 in the diabetic heart, in which GLP-1 signalling is likely 
to be different, remain unknown and clearly need to be defined in order to fully assess the 
therapeutic potential of GLP-1 in this setting. A
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SUMMARY AND FUTURE PERSPECTIVE 
 Over recent years it has become clear that GLP-1 exerts important actions on the 
cardiovascular system in both health and disease in addition to its prototypic effects on 
glycaemic control (Grieve et al., 2009) and also confers beneficial effects on the 
cardiovascular risk profile in diabetic patients. However, emerging evidence now strongly 
suggests that GLP-1 exerts specific cardiovascular actions in diabetes and may attenuate the 
development and progression of associated cardiovascular complications (summarised in 
Figure 1), although the precise mechanisms are yet to be established with several candidate 
pathways proposed (see Figure 2). Nonetheless, it is important to note that the majority of 
data pointing towards such beneficial effects are largely experimental and that equivalent 
information on the cardiovascular actions of GLP-1 in the clinical setting of diabetes is 
somewhat lacking, particularly in relation to its chronic effects. In this regard, the first large-
scale GLP-1 clinical trials to assess cardiovascular outcomes after long-term treatment 
(SAVOR-TIMI 53, EXAMINE) have recently reported that chronic DPP-4 inhibition with 
either saxagliptin or  apogliptin had no significant effects on their primary composite end 
points of cardiovascular death, or non-fatal MI/stroke (Scirica et al., 2013; White et al., 2013), 
although it should be noted that SAVOR-TIMI 53 reported a 27% increase in hospitalisation 
for heart failure. However, until the results of several ongoing clinical trials investigating the 
chronic cardiovascular effects of GLP-1R agonists are known (summarised in Table 1 
together with further DPP-4 inhibitor trials), in which circulating GLP-1 levels will be much 
higher than those achieved using DPP-4 inhibitors, no conclusions can be drawn on either the 
potential clinical cardiovascular benefits or safety of GLP-1 based therapies in diabetes. 
Nonetheless, the apparent complexity of cardiovascular GLP-1 signalling under both normal 
and diabetic conditions clearly suggests that it is likely that selective targeting of specific A
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aspects of CVD may be required in order to realise optimal benefits of GLP-1 targeting in this 
setting. 
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FIGURE LEGENDS 
 
Figure 1  Summary of the cardiovascular actions of GLP-1 in diabetes. GLP-1 exerts indirect 
cardiovascular benefits in diabetes secondary to its established metabolic actions and 
subsequent reduction of cardiovascular risk factors. In addition, GLP-1 promotes direct 
cardiovascular benefits which confer protection against CVD and heart failure, the latter of 
which may occur via direct myocardial actions or secondary to reduced hypertension and 
coronary atherosclerosis. 
 
Figure 2  Proposed mechanisms underlying the reported cardiovascular actions of GLP-1. 
Although it is well established that GLP-1 exerts several beneficial effects on the 
cardiovascular system relevant to diabetes, such as reduction of metabolic CVD risk factors, 
blood pressure modulation, improved vascular function, decreased atherosclerosis, promotion 
of angiogenesis, and attenuation of adverse cardiac remodelling, the precise mechanisms are 
yet to be established, although several pathways have been proposed which are the focus of 
further investigation. EC, endothelial cell; ECM, extracellular matrix; PKC, protein kinase C; 
SDF, stromal cell-derived factor 1α; SR, sarcoplasmic reticulum; VEGF, vascular endothelial 
growth factor. 
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TABLE 1: Current long-term clinical trials of GLP-1 based therapies on cardiovascular outcomes 
Study name Drug Administration 
Estimated 
patient 
enrolment 
Primary outcome(s) 
Expected end 
date 
NCT identifier 
 
EXSCEL 
 
Exenatide 
 
Subcutaneous injection, 2 
mg, once weekly 
 
14,000 
 
Rate of CV death, non-fatal MI or 
non-fatal stroke 
 
December 2017 
 
NCT01144338 
 
LEADER 
 
Liraglutide 
 
Subcutaneous injection, 
1.8 mg, once daily 
 
9,340 
 
Time to CV death, non-fatal MI or 
non-fatal stroke 
 
October 2015 
 
NCT01179048 
 
ELIXA 
 
Lixisenatide 
 
Subcutaneous injection, 20 
μg, once daily 
 
6,000 
 
Time to first primary CV event 
 
January 2015 
 
NCT01147250 
 
REWIND 
 
Dulaglutide 
 
Subcutaneous injection, 
1.5 mg, once weekly 
 
9622 
 
Time to CV death, non-fatal MI, or 
non-fatal stroke 
 
August 2019 
 
NCT01394952 
 
TECOS 
 
Sitagliptin 
 
Oral, 50 or 100 mg, once 
daily 
 
14,000 
 
Time to first CV event 
 
December 2014 
 
NCT00790205 
 
CAROLINA 
 
Linagliptin 
 
Not specified 
 
8,300 
 
Time to CV death, non-fatal MI, 
non-fatal stroke and hospitalisation 
for unstable angina pectoris 
 
January 2018 
 
NCT01897532 
 
CARMELINA 
 
Linagliptin 
 
Oral, 5 mg, once daily 
 
6,000 
 
Time to CV death, non-fatal MI, 
non-fatal stroke and hospitalisation 
for unstable angina pectoris 
 
 
September 2018 
 
NCT01243424 
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